Feasibility of a Type 1 Diabetes Primary Prevention Trial Using 2000 IU Vitamin D3 in Infants from the General Population with Increased HLA‐Associated Risk | Zendy

WICKLOW BRANDY A. | Zendy; TABACK SHAYNE P. | Zendy

Premium

Feasibility of a Type 1 Diabetes Primary Prevention Trial Using 2000 IU Vitamin D3 in Infants from the General Population with Increased HLA‐Associated Risk

Author(s) -

WICKLOW BRANDY A.,

TABACK SHAYNE P.

Publication year - 2006

Publication title -

annals of the new york academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.712

H-Index - 248

eISSN - 1749-6632

pISSN - 0077-8923

DOI - 10.1196/annals.1375.047

Subject(s) - medicine , vitamin d and neurology , randomized controlled trial , diabetes mellitus , population , type 2 diabetes , vitamin , type 1 diabetes , human leukocyte antigen , pediatrics , primary prevention , immunology , endocrinology , disease , environmental health , antigen

Recent epidemiologic, immunologic, and NOD mouse studies suggest that intervention in the vitamin D system may be a successful method to prevent type 1 diabetes. Newborns at increased HLA‐associated risk are randomized to receive either 400 or 2000 IU vitamin D3 by 1 month of age. We show that recruitment of babies from the general population for identification of HLA‐associated risk status followed by enrollment to a randomized controlled prevention trial is feasible in Canada.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research